29 related articles for article (PubMed ID: 8832225)
1. Differences in Neuronal Numbers, Morphology, and Developmental Apoptosis in Mice Nigra Provide Experimental Evidence of Ontogenic Origin of Vulnerability to Parkinson's Disease.
Vidyadhara DJ; Yarreiphang H; Raju TR; Alladi PA
Neurotox Res; 2021 Dec; 39(6):1892-1907. PubMed ID: 34762290
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
3. Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice.
Miville-Godbout E; Bourque M; Morissette M; Al-Sweidi S; Smith T; Mochizuki A; Senanayake V; Jayasinghe D; Wang L; Goodenowe D; Di Paolo T
PLoS One; 2016; 11(3):e0151020. PubMed ID: 26959819
[TBL] [Abstract][Full Text] [Related]
4. PET/SPECT imaging agents for neurodegenerative diseases.
Zhu L; Ploessl K; Kung HF
Chem Soc Rev; 2014 Oct; 43(19):6683-91. PubMed ID: 24676152
[TBL] [Abstract][Full Text] [Related]
5. MPTP mouse models of Parkinson's disease: an update.
Meredith GE; Rademacher DJ
J Parkinsons Dis; 2011; 1(1):19-33. PubMed ID: 23275799
[TBL] [Abstract][Full Text] [Related]
6. 5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABA A receptor radioligands.
Li X; Jung YW; Snyder SE; Blair J; Sherman PS; Desmond T; Frey KA; Kilbourn MR
Nucl Med Biol; 2008 Jul; 35(5):549-59. PubMed ID: 18589299
[TBL] [Abstract][Full Text] [Related]
7. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
8. Imaging the vesicular monoamine transporter.
Frey KA; Koeppe RA; Kilbourn MR
Adv Neurol; 2001; 86():237-47. PubMed ID: 11553983
[TBL] [Abstract][Full Text] [Related]
9. The vesicular monoamine transporter: from chromaffin granule to brain.
Henry JP; Sagné C; Bedet C; Gasnier B
Neurochem Int; 1998 Mar; 32(3):227-46. PubMed ID: 9587917
[TBL] [Abstract][Full Text] [Related]
10. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains.
Kilbourn M; Frey K
Eur J Pharmacol; 1996 Jun; 307(2):227-32. PubMed ID: 8832225
[TBL] [Abstract][Full Text] [Related]
11. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
12. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
Frey K; Kilbourn M; Robinson T
Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
Ekue A; Boulanger JF; Morissette M; Di Paolo T
J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
[TBL] [Abstract][Full Text] [Related]
14. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific.
Kilbourn M; Lee L; Vander Borght T; Jewett D; Frey K
Eur J Pharmacol; 1995 May; 278(3):249-52. PubMed ID: 7589162
[TBL] [Abstract][Full Text] [Related]
15. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice.
Gainetdinov RR; Fumagalli F; Wang YM; Jones SR; Levey AI; Miller GW; Caron MG
J Neurochem; 1998 May; 70(5):1973-8. PubMed ID: 9572281
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
